Introduction
Hodgkin's disease (HD) is characterized by sparse, malignant Hodgkin's Reed-Sternberg (H-RS) cells within a larger population of normal lymphocytes infiltrating the lymph node. The aberrantly large H-RS cells strongly express the lymphocyte activation marker CD30, easily distinguishing them from the surrounding normal tissue. H-RS cells, while slow growing, produce significant levels of cytokines including IL-13 1 stimulating the growth of recruited lymphoid cells, resulting in a localized chronic activation state. This pathology presents a challenge to chemotherapy regimens as the activated normal cells may be preferentially affected, with limited efficacy against the H-RS.
Expression of CD30, a member of the tumor necrosis factor receptor (TNFr) superfamily, is transient during lymphocyte activation but constitutively present in hematologic malignancies including anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma, and embryonal carcinoma. [2] [3] [4] The highly restricted expression of CD30 presents a compelling tumor target for therapeutic mAbs, 5 immunotoxins, 6 and antibody-drug conjugates. 7 CD30 ligation by CD153 (CD30L) on HD cells induces signaling through the TNF receptor-associated factors (primarily TRAF-2 and -6) and subsequent NF-kB activation. 8 The efficacy of two clinically approved therapeutic mAbs, Herceptin s and Rituxan s , is demonstrated, in part, by their sensitization of target cells to established chemotherapeutics in experimental models 9, 10 and clinically. 11, 12 Generally, the extended pharmacokinetics of mAbs 13, 14 could produce near continuous sensitization of tumor during sequential waves of appropriate chemotherapy. mAbs to the TNF receptors DR4 and DR5 can transduce death signals resulting in synergistic antitumor activity when combined with cisplatin and doxorubicin, but not paclitaxel, 15 suggesting that optimal combinations of signaling mAbs and chemotherapeutics can be developed based on specific targeted cellular pathways.
The therapeutic anti-CD30 mAb SGN-30 has been shown to induce growth arrest and DNA fragmentation in HD and ALCL lines in vitro and antitumor effect in vivo. 5 The current study investigates cellular events leading to SGN-30-mediated growth arrest. Growth-regulating genes induced by SGN-30 treatment were identified using cDNA microarrays and apoptosis induced in treated cultures assessed by Annexin V/propidium iodide staining. Using the Combination Effects method, we assessed how SGN-30 might modulate the effects of therapeutics commonly used to treat HD, and report the broadly synergistic interaction between SGN-30 and multiple chemotherapeutics currently used in the treatment of HD.
Materials and methods

Cell lines and drugs
The HD cell line L540cy 5 was provided by A Engert, University Hospital, Cologne, Germany. The parent L540, L428 (HD) and Karpas 299 (ALCL) were from the DSMZ (Braunschweig, Germany). Ramos (NHL) was from ATCC (Manassas, VA, USA). Karpas 299, L428, and Ramos cells were grown in RPMI 1640 þ 10% FBS (Invitrogen, Carlsbad, CA, USA). L540 and L540cy were grown in RPMI 1640 þ 20% FBS. Cells were cultured at 371C, 5% CO 2 in a humidified incubator. Drug stocks of doxorubicin, vinblastine, cisplatin, cytarabine, etoposide (Sigma, St Louis, MO, USA), and chlorambucil (LKT Labs, St Paul, MN, USA) were prepared in DMSO and stored at À201C until use. Bleomycin (Faulding Labs, Paramus, NJ, USA) was prepared in sterile water and stored at 41C until use.
Activation of NF-kB
L540cy cells were incubated for progressive times with 100 ng/ml SGN-30 crosslinked (XL) by 1 mg/ml goat-anti-human F(ab) (Jackson Immunoresearch, West Grove, PA, USA). Following collection, nuclear extracts were prepared and NF-kB activity was measured using the TransAM NF-kB Chemi, chemiluminescent binding assay (Active Motif, Carlsbad, CA). 
Analysis of gene expression changes
Induction of apoptosis by SGN-30
L540cy cells (2 Â 10 5 cells) were plated in 3 ml of complete medium in 12-well plates and treated for progressive times with 1 mg/ml of XL SGN-30 or an irrelevant IgG. Aliquots were collected, stained with Annexin V-FITC (Becton Dickinson), washed, stained with propidium iodide (PI) staining and evaluated by flow cytometry.
In vitro drug combination studies
L540cy or L428 cells (5 Â 10 3 cells/well) were seeded in 96-well plates containing 100 ml of complete medium. XL SGN-30 was prepared with a 10-fold excess of goat-anti-human F(ab) 0 2 (Jackson Immunoresearch, West Grove, PA, USA) before serial dilution. Cultures were treated with XL SGN-30 dilutions (50 ml/ well) and incubated for 24 h at 371C, followed by drug addition (50 ml/well) and incubation for a further 72 h. Cultures were pulse-labeled for the final 4 h with 0.5 mCi 3 H-thymidine (TdR)/ well. Cultures were frozen at À801C and thawed to facilitate DNA release, harvested onto GFC plates and 3 H-TdR incorporation quantified by scintillation counting (Topcount, Packard, Meriden, CT, USA). IC 50 values for each drug were determined from quadruplicate titrations. Data were analyzed in Excel to determine the fraction affected (fa) at each tested concentration. The test concentrations and corresponding fa values were used to derive Combination Index (CI) values using the Calcusyn software package (Biosoft, Cambridge, UK) using the median effect/combination-index isobologram method. 16 CI values from triplicate experiments were averaged across the effect range, and the means tested for significant differences from a hypothetical CI value of 1.0 using a one-sample t-test in GraphPad Prism v.4.00 (GraphPad Software, San Diego, CA, USA). 17 In this model, drug interactions with a CI significantly different from 1.0 (Po0.05) were placed into two classes; CIo1.0 were synergistic, CI41.0 antagonistic, and any CI values not significantly different from 1.0 considered additive. Mutually nonexclusive CI values were used in this study. 16 
Xenograft studies of HD tumors
L540cy s.q. xenograft tumors were established in SCID mice and grown to a mean tumor volume of 100 mm 3 prior to separation into treatment groups (10 mice/group). Treatments were administered i.p. every 4 days for a total of three injections (q4d Â 3) for bleomycin or five i.v. injections (q4d Â 5) for SGN-30. Groups were treated with either SGN-30 at 4 mg/kg, bleomycin at 15 U/kg, or SGN-30 at 4 mg/kg þ bleomycin at 15 U/kg (schedules identical to each drug individually), or not treated. Tumor volumes were measured twice weekly and the mean tumor volume was calculated (length Â width 2 /2). All studies were carried out under IACUC guidelines.
Results
SGN-30 induces NF-kB activation
L540cy cells show constitutive activation of the transcription factor NF-kB, a trait speculated to provide increased tumor resistance to chemotherapy. 18 However, activation in these cells, as measured by increased NF-kB binding to a promoter DNA target sequence (Figure 1a ), significantly increased (P ¼ 0.0001, 2-way ANOVA) within 1 h of SGN-30 treatment and was durable for 424 h post-treatment initiation.
SGN-30 treatment modulates expression of genes involved in cell cycle control
Altered gene expression subsequent to NF-kB activation in L540 cells was evaluated by cDNA microarray analysis following 16 h incubation with XL SGN-30. Compared to those of untreated cells (Figure 1b) , genes induced by SGN-30 included those associated with intercellular cellular communication, cell cycle control, and stress response (Figure 1c ). These included ICAM-1, cyclin D2, c-myc, and p21, genes previously reported to be modulated by NF-kB or NF-kB responsive molecules, [19] [20] [21] germane to the NF-kB activity described above. Genes decreasing upon SGN-30 treatment included GADD153, neuroleukin/phosphohexose isomerase, and vascular endothelial growth factor (VEGF).
Validation of p21 mRNA induction in the L540 subline, L540cy, was evaluated by Northern analysis (Figure 2a ). Both L540 and L540cy expressed p21 mRNA at a basal level ( Figures  1b and 2a , respectively) and both increased dramatically when treated with SGN-30. ICAM-1 and p21, both induced 43-fold at the message level, whose biologic functions are relevant to growth arrest by SGN-30 5 were further evaluated at the protein level. As shown in Figure 2b 
SGN-30 treatment leads to apoptosis
Standard biomarkers of apoptosis, Annexin V and PI staining, were used to evaluate membrane phospholipid alterations and integrity following growth inhibition by SGN-30. L540cy cells were treated with XL SGN-30 and stained at progressive times. In control IgG-treated cultures, Annexin V þ and Annexin V þ /PI þ cells remained less than 8% throughout the study (Figure 3, right column) . In contrast, cells became Annexin V þ within 24 h of SGN-30 exposure (Figure 3 , left column), and staining intensity further increased at 48 h. PI staining, indicating loss of membrane integrity, was detectable at 48 h and after 72 h, B60% of the cells exposed to SGN-30 were Annexin V þ . Taken together, these data show exposure to SGN-30 results in induction of apoptosis in these CD30
þ HD cells by 24 h.
SGN-30 pretreatment sensitizes HD cells to standard chemotherapeutics
To assess whether altered gene expression or a preapoptotic state could sensitize SGN-30 treated cells to a second cytotoxic insult, L540cy and L428 cells were exposed to XL SGN-30 followed 24 h later by titrations of chemotherapeutics of different cytotoxic classes. Pretreatment with XL SGN-30 was intended to model a clinical setting where antibody would persist in circulation after treatment and be clustered by Fc receptors. The median effect/combination index (CI) isobologram model, 16 used for data analysis, is a useful preclinical tool to determine the potential for drugs to be used in combination. 22 A numerical value, assigned to each drug combination at predefined dose levels, enables quantitative drug/drug interaction comparisons between different drug combinations, in contrast to traditional, qualitative isobologram analysis. The CI values assign interactions into three categories: synergism, additivity, and antagonism. Synergism results when two (or more) drugs impact the same target or pathways in a system, as in blocking of a DNA repair pathway in the presence of a DNAdamaging agent. Just such a synergistic relationship has been shown for the therapeutic mAb Herceptin s in combination with the DNA alkylator, cisplatin. 9 Test drugs were selected for diverse mechanisms of action and current use in therapies for HD, including components of both doxorubicin-bleomycin-vinblastine-dacarbazine (ABVD) and ifosfamide-carboplatin-etoposide (ICE) regimens. 23, 24 Test concentrations were bracketed about multiples of the IC 50 determined for each drug individually and combinations maintained a constant ratio between the two drugs. In both cell lines, all drug combinations tested resulted in at least additive interactions ( Figure 4 ) and several resulted in significant synergy (defined as significantly lower than a CI ¼ 1.0, 1 sample t-test with a ¼ 0.05): bleomycin (Po0.001), cytarabine (Po0.01), and etoposide (Po0.0001). lymphomas. 25 Clinical demonstrations of the therapeutic mAbs Herceptin s and Rituxan s selectively increasing antitumor response to chemotherapy has prompted our examination of whether H-RS cells could be effectively sensitized to established cytotoxics by treatment with SGN-30.
CD30 ligation on HD cells promotes downstream TRAF clustering and subsequent activation of NF-kB activation. 8 Treatment of L540cy cells with SGN-30 resulted in rapid (o1 h) and persistent (424 h) activation of NF-kB. SGN-30 treatment led to numerous changes in the transcriptome, including genes regulated by NF-kB and those involved in cell cycle control. Two gene products, p21 and ICAM-1, whose transcript levels increased, have biological effects consistent with growth and apoptotic changes seen in SGN-30-treated cells. 5 Previous reports have demonstrated p21 induction in anti-CD30-treated ALCL lines 26, 27 and we demonstrate herein that SGN-30 can extend this effect to HD cells. SGN-30 activity in vitro is enhanced by secondary antibody crosslinking (XL), suggesting a requirement for CD30 molecules to multimerize in order to signal effectively. In vivo, this clustering may be mediated by Fc receptors. Expression of p21 can be induced through p53-dependent, 28 -independent, 26, 29 or extracellular signals, 30 leading to cell cycle arrest in G 1 phase via binding to cyclin A-CDK2 complexes and to PCNA. 31 p21 is detected in HD biopsies 32 and its induction by SGN-30 may further sensitize tumor cells in vivo.
We have previously shown that SGN-30 can produce DNA fragmentation in both HD and ALCL lines, 5 and show here, using Annexin V and PI as apoptotic biomarkers, that SGN-30 acts via a classical apoptotic pathway. This occurs despite an apparent lack of death domains in the cytoplasmic tail of CD30 found in other TNFr family members. It is unclear whether absence of this domain in CD30 accounts for a lack of caspase activation in cell lines growth arrested by other anti-CD30 mAbs, 26 as apoptosis triggered through CD30 appears associated with caspases-1 and -3 activation in transgenic mice. Apoptosis in this system could be blocked by Bcl-2 overexpression, suggesting that mitochondrial damage rather than activation of caspase 8 may be key in CD30-mediated apoptosis. 33 Our data show that whereas 450% of the cells treated with SGN-30 are Annexin V þ by 72 h, a smaller percentage are coincidently PI þ . SGN-30 can thus affect membrane inversion without a coincident loss in membrane integrity. Such apoptotic priming could stem from increased p21 or c-myc, as both molecules have been shown to sensitize cells to apoptosis by other agents, 34 and chemotherapeutics including doxorubicin and 5-fluorouracil, that induce proapoptotic molecules such as caspases, also produce activation of p21. 28, 35 Importantly, SGN-30 combined with bleomycin, cytarabine, and etoposide resulted in significant synergies in tumor cell killing in both cell lines (Po0.001 in all cases). Whereas induction of p21 could be speculated to antagonize chemotherapeutic effects, due to accumulation of arrested cells, 26 these results are encouraging. The anti-CD30 mAb 5F11 combined with chemotherapeutics also demonstrated additive effects in HD models. 36 SGN-30 binds to a different epitope than 5F11 and potentially generates a different signal. 37 The in vitro synergy of SGN-30 combined with bleomycin was reflected in increased efficacy of the combination against established HD tumor xenografts. The sensitization provided by SGN-30 may be critical to the elimination of refractive H-RS cells receiving suboptimal doses of standard chemotherapeutics.
The mechanism of synergy, while likely attributed to genebased alterations induced by SGN-30, remains to be resolved. Current and prior studies 5 suggest that SGN-30 triggers apoptosis and growth inhibition pathways (eg p21 induction, G 1 /S arrest) complimentary or sensitizing to DNA damageinduced pathways. Several of the chemotypes evaluated result in DNA damage through different mechanisms. Herceptin s tumor sensitization has been its attributed to impaired DNA repair, and has similarly been shown to produce G 1 arrest and synergistic killing with cisplatin and thiotepa, while producing additive effects when combined with taxanes, vinca alkaloids, and anthracyclines. 9, 17 SGN-30 presents a promising opportunity to selectively sensitize HD to established therapeutics. Antigen expression is primarily restricted to the infrequent and highly CD30-positive malignant Reed-Sternberg cells; and sensitization to chemotherapy of CD30-negative tissues would not be expected. In the preclinical models presented here, HD cells treated in vitro and in vivo with SGN-30 were highly sensitized to multiple agents including those employed in first-line therapies against HD. SGN-30 has shown promising antitumor activity in ongoing clinical studies and current data suggest its synergy with established regimens may provide even greater efficacy in the treatment of CD30-positive malignancies.
